Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03892967 · ClinicalTrials.gov registry record · NA

Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial

A NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
50,207
Enrollment target
1
Study location

NCT03892967: Completed NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by Mayo Clinic.

NCT03892967 is a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that has completed, run by Mayo Clinic. The registered enrollment target is 50,207 participants, above the 856-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (5765% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03892967, a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
50,207 participants
Enrollment target
1
Study location

Study Summary

This early phase I trial investigates enhanced, electronic health record (EHR)-facilitated cancer system control. Cancer and its treatment are often associated with severe, disabling symptoms that have been causally linked to diminished survival, increased healthcare utilization, degraded quality of life, unemployment, and non-adherence to recommended cancer treatments. Collaborative case management for control of moderate or worse sleep disturbance, pain, anxiety, depression, fatigue (SPADE symptoms), and physical dysfunction among cancer survivors and patients with cancer may improve quality of life, symptom severity, and adherence to cancer treatment, and may also reduce need for acute care.

Primary Outcome

Measured by 11-point Numeric Rating Scales (NRS) for sleep disturbance, pain, anxiety, depression, fatigue, and physical function impairment at clinic encounters. Symptoms were assessed on a scale of 0 to 10 with higher scores indicating worse outcomes. Changes in sleep disturbance, pain, anxiety, depression, fatigue, and physical function impairment from baseline score were modeled jointly as a co-primary outcome.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • OTHER Interview

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 50,207 participants
Start Date 2019-03-28
Est. Completion 2023-01-31
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT03892967 record still lists

NCT03892967 is an interventional study that assigns participants to a tested intervention. Its 50,207 participants enrollment target places it among the larger protocols in the corpus, above the 856-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (5765% higher).

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03892967 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT03892967 about?

NCT03892967 is a clinical study titled "Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial". This early phase I trial investigates enhanced, electronic health record (EHR)-facilitated cancer system control. Cancer and its treatment are often associated with severe, disabling symptoms that have been causally linked to diminished survival, increased healthcare utilization, degraded quality of...

What is the current status of trial NCT03892967?

This trial is currently completed. It is a NA study. The enrollment target is 50,207 participants. The study started on 2019-03-28. Estimated completion is 2023-01-31.

What conditions does trial NCT03892967 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT03892967?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Interview (OTHER).

Who is sponsoring clinical trial NCT03892967?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03892967 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03892967's enrollment target sits among peer trials

50,207 1st of 176 higher than 176 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00500123 · 50,000 participants

    The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

  • NCT01885299 · 50,000 participants

    RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

  • NCT03452774 · 50,000 participants

    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • NCT04629586 · 50,000 participants

    The T1D Exchange Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03892967, the US trial registry maintained by the National Library of Medicine. NCT03892967 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.